O	0	8	Efficacy
O	9	11	of
B-intervention	12	18	ginger
O	19	22	for
O	23	34	prophylaxis
O	35	37	of
B-condition	38	50	chemotherapy
I-condition	50	51	-
I-condition	51	58	induced
I-condition	59	65	nausea
I-condition	66	69	and
I-condition	70	78	vomiting
O	79	81	in
B-eligibility	82	88	breast
I-eligibility	89	95	cancer
I-eligibility	96	104	patients
I-eligibility	105	114	receiving
I-eligibility	115	125	adriamycin
I-eligibility	125	126	-
I-eligibility	126	142	cyclophosphamide
I-eligibility	143	150	regimen
O	150	151	:
O	152	153	a
O	154	164	randomized
O	164	165	,
O	166	172	double
O	172	173	-
O	173	178	blind
O	178	179	,
O	180	187	placebo
O	187	188	-
O	188	198	controlled
O	198	199	,
O	200	209	crossover
O	210	215	study
O	215	216	.

O	217	220	The
O	221	228	purpose
O	229	231	of
O	232	236	this
O	237	242	study
O	243	245	is
O	246	248	to
O	249	258	determine
O	259	262	the
O	263	271	efficacy
O	272	274	of
O	275	281	ginger
O	282	285	for
O	286	294	reducing
O	295	307	chemotherapy
O	307	308	-
O	308	315	induced
O	316	322	nausea
O	323	326	and
O	327	335	vomiting
O	336	337	(
O	337	341	CINV
O	341	342	)
O	343	345	in
O	346	352	breast
O	353	359	cancer
O	360	368	patients
O	369	378	receiving
O	379	389	adriamycin
O	390	393	and
O	394	410	cyclophosphamide
O	411	412	(
O	412	414	AC
O	414	415	)
O	416	424	regimens
O	424	425	.

O	426	428	We
O	429	437	enrolled
B-eligibility	438	444	breast
I-eligibility	445	451	cancer
I-eligibility	452	460	patients
I-eligibility	461	470	receiving
I-eligibility	471	473	AC
I-eligibility	474	477	who
I-eligibility	478	489	experienced
I-eligibility	490	498	moderate
I-eligibility	499	501	to
I-eligibility	502	508	severe
I-eligibility	509	515	nausea
I-eligibility	516	518	or
I-eligibility	519	527	vomiting
I-eligibility	528	534	during
I-eligibility	535	538	the
I-eligibility	539	544	first
I-eligibility	545	557	chemotherapy
I-eligibility	558	563	cycle
O	563	564	.

O	565	573	Subjects
O	574	578	were
O	579	589	randomized
O	590	592	to
O	593	600	receive
O	601	602	a
O	603	606	500
O	606	607	-
O	607	609	mg
O	610	616	ginger
O	617	624	capsule
O	625	627	or
B-control	628	635	placebo
O	636	641	twice
O	642	643	a
O	644	647	day
O	648	651	for
O	652	653	5
O	654	658	days
O	659	667	starting
O	668	670	on
O	671	674	the
O	675	680	first
O	681	684	day
O	685	687	of
O	688	691	the
O	692	698	second
O	699	701	AC
O	702	707	cycle
O	708	711	and
O	712	716	were
O	717	725	switched
O	726	728	to
O	729	732	the
O	733	738	other
O	739	748	treatment
O	749	751	in
O	752	755	the
O	756	761	third
O	762	767	cycle
O	767	768	.

O	769	772	All
O	773	785	participants
O	786	790	also
O	791	799	received
O	800	811	ondansetron
O	812	815	and
O	816	829	dexamethasone
O	830	833	for
O	834	838	CINV
O	839	850	prophylaxis
O	850	851	.

O	852	858	Nausea
O	859	867	severity
O	868	871	was
O	872	880	recorded
O	881	885	once
O	886	887	a
O	888	891	day
O	892	898	during
O	899	902	the
O	903	908	first
O	909	910	5
O	911	915	days
O	916	918	of
O	919	923	each
O	924	929	cycle
O	929	930	.

O	931	934	The
O	935	942	primary
O	943	950	outcome
O	951	954	was
B-outcome-Measure	955	964	reduction
I-outcome-Measure	965	967	in
I-outcome-Measure	968	974	nausea
I-outcome-Measure	975	980	score
O	980	981	.

B-total-participants	982	988	Thirty
I-total-participants	988	989	-
I-total-participants	989	993	four
O	994	1002	subjects
O	1003	1004	(
O	1004	1006	68
O	1007	1013	cycles
O	1014	1016	of
O	1017	1019	AC
O	1019	1020	)
O	1021	1025	were
O	1026	1034	enrolled
O	1034	1035	.

O	1036	1040	Mean
O	1041	1042	(
O	1042	1047	range
O	1047	1048	)
O	1049	1056	maximum
B-outcome	1057	1063	nausea
I-outcome	1064	1069	score
O	1070	1072	in
O	1073	1076	the
O	1077	1082	first
O	1083	1085	AC
O	1086	1091	cycle
O	1092	1095	was
O	1096	1098	58
O	1099	1100	(
O	1100	1102	40
O	1102	1103	-
O	1103	1105	90
O	1105	1106	)
O	1106	1107	.

B-total-participants	1108	1114	Thirty
I-total-participants	1114	1115	-
I-total-participants	1115	1120	three
O	1121	1129	subjects
O	1130	1131	(
O	1131	1133	97
O	1134	1135	%
O	1135	1136	)
O	1137	1145	received
O	1146	1149	the
O	1150	1154	same
O	1155	1157	AC
O	1158	1163	doses
O	1164	1166	in
O	1167	1170	the
O	1171	1177	second
O	1178	1180	as
O	1181	1183	in
O	1184	1187	the
O	1188	1193	third
O	1194	1199	cycle
O	1199	1200	.

O	1201	1205	Mean
O	1206	1207	(
O	1207	1208	±
O	1208	1216	standard
O	1217	1222	error
O	1222	1223	)
O	1224	1231	maximum
B-outcome	1232	1238	nausea
I-outcome	1239	1245	scores
O	1246	1248	in
O	1249	1257	patients
O	1258	1267	receiving
O	1268	1274	ginger
O	1275	1278	and
O	1279	1286	placebo
O	1287	1291	were
B-iv-cont-mean	1292	1294	35
I-iv-cont-mean	1294	1295	.
I-iv-cont-mean	1295	1297	36
O	1298	1299	(
B-iv-cont-sd	1299	1300	±
I-iv-cont-sd	1300	1301	4
I-iv-cont-sd	1301	1302	.
I-iv-cont-sd	1302	1304	43
O	1304	1305	)
O	1306	1309	and
B-cv-cont-mean	1310	1312	32
I-cv-cont-mean	1312	1313	.
I-cv-cont-mean	1313	1315	17
O	1316	1317	(
B-cv-cont-sd	1317	1318	±
I-cv-cont-sd	1318	1319	3
I-cv-cont-sd	1319	1320	.
I-cv-cont-sd	1320	1322	71
O	1322	1323	)
O	1323	1324	,
O	1325	1337	respectively
O	1337	1338	.

O	1339	1342	The
O	1343	1353	difference
O	1354	1356	in
O	1357	1361	mean
O	1362	1369	maximum
B-outcome	1370	1376	nausea
I-outcome	1377	1383	scores
O	1384	1387	was
O	1388	1389	3
O	1390	1391	(
O	1391	1393	95
O	1394	1395	%
O	1396	1406	confidence
O	1407	1415	interval
O	1415	1416	,
O	1417	1418	-
O	1418	1419	3
O	1420	1422	to
O	1423	1424	9
O	1424	1425	;
O	1426	1427	P
O	1428	1429	=
O	1430	1431	0
O	1431	1432	.
O	1432	1433	3
O	1433	1434	)
O	1434	1435	.

O	1436	1441	There
O	1442	1446	were
O	1447	1449	no
O	1450	1461	significant
O	1462	1473	differences
O	1474	1481	between
O	1482	1488	ginger
O	1489	1492	and
O	1493	1500	placebo
O	1501	1503	in
O	1504	1509	terms
O	1510	1512	of
B-outcome	1513	1521	vomiting
I-outcome	1522	1531	incidence
I-outcome	1532	1535	and
I-outcome	1536	1544	severity
O	1544	1545	,
B-outcome	1546	1552	rescue
I-outcome	1553	1563	medication
I-outcome	1564	1567	use
O	1567	1568	,
B-outcome	1569	1581	chemotherapy
I-outcome	1582	1592	compliance
O	1592	1593	,
O	1594	1597	and
B-outcome	1598	1605	adverse
I-outcome	1606	1612	events
O	1612	1613	.

O	1614	1620	Ginger
O	1621	1622	(
O	1622	1625	500
O	1626	1628	mg
O	1628	1629	)
O	1630	1635	twice
O	1636	1641	daily
O	1642	1645	was
O	1646	1650	safe
O	1650	1651	,
O	1652	1655	but
O	1656	1665	conferred
O	1666	1668	no
O	1669	1679	additional
O	1680	1687	benefit
O	1688	1690	in
O	1691	1696	terms
O	1697	1699	of
O	1700	1708	reducing
O	1709	1715	nausea
O	1716	1724	severity
O	1725	1727	in
O	1728	1734	breast
O	1735	1741	cancer
O	1742	1750	patients
O	1751	1760	receiving
O	1761	1763	AC
O	1764	1767	and
O	1768	1779	ondansetron
O	1780	1783	and
O	1784	1797	dexamethasone
O	1798	1801	for
O	1802	1806	CINV
O	1807	1818	prophylaxis
O	1818	1819	.
